Gágyor, Ildikó

[["dc.bibliographiccitation.artnumber","CD001942"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Cochrane Database of Systematic Reviews"],["dc.contributor.author","Gagyor, Ildiko"],["dc.contributor.author","Daly, Fergus"],["dc.contributor.author","Somasundara, Dhruvashree"],["dc.contributor.author","Sullivan, Michael"],["dc.contributor.author","Gammie, Fiona"],["dc.contributor.author","Sullivan, Frank"],["dc.contributor.author","Madhok, Vishnu B."],["dc.date.accessioned","2020-12-10T14:05:52Z"],["dc.date.available","2020-12-10T14:05:52Z"],["dc.date.issued","2016"],["dc.description.abstract","Background Inflammation and oedema of the facial nerve are implicated in causing Bell's palsy. Corticosteroids have a potent anti-inflammatory action that should minimise nerve damage. This is an update of a review first published in 2002 and last updated in 2010. Objectives To determine the effectiveness and safety of corticosteroid therapy in people with Bell's palsy. Search methods On 4 March 2016, we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and LILACS. We reviewed the bibliographies of the randomised trials and contacted known experts in the field to identify additional published or unpublished trials. We also searched clinical trials registries for ongoing trials. Selection criteria Randomised trials and quasi-randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group receiving no therapy considered effective for this condition, unless the same therapy was given in a similar way to the experimental group. Data collection and analysis We used standard Cochrane methodology. The main outcome of interest was incomplete recovery of facial motor function (i.e. residual facial weakness). Secondary outcomes were cosmetically disabling persistent sequelae, development of motor synkinesis or autonomic dysfunction (i.e. hemifacial spasm, crocodile tears) and adverse effects of corticosteroid therapy manifested during follow-up. Main results We identified seven trials, with 895 evaluable participants for this review. All provided data suitable for the primary outcome meta-analysis. One of the trials was new since the last version of this Cochrane systematic review. Risk of bias in the older, smaller studies included some unclear-or high-risk assessments, whereas we deemed the larger studies at low risk of bias. Overall, 79/452 (17%) participants allocated to corticosteroids had incomplete recovery of facial motor function six months or more after randomisation; significantly fewer than the 125/447 (28%) in the control group (risk ratio (RR) 0.63, 95% confidence interval (CI) 0.50 to 0.80, seven trials, n = 895). The number of people who need to be treated with corticosteroids to avoid one incomplete recovery was 10 (95% CI 6 to 20). The reduction in the proportion of participants with cosmetically disabling sequelae six months after randomisation was very similar in the corticosteroid and placebo groups (RR 0.96, 95% CI 0.40 to 2.29, two trials, n = 75, low-quality evidence). However, there was a significant reduction in motor synkinesis during follow-up in participants receiving corticosteroids (RR 0.64, 95% CI 0.45 to 0.91, three trials, n = 485, moderate-quality evidence). Three studies explicitly recorded the absence of adverse effects attributable to corticosteroids. One trial reported that three participants receiving prednisolone had temporary sleep disturbances and two trials gave a detailed account of adverse effects occurring in 93 participants, all non-serious; the combined analysis of data from these three trials found no significant difference in adverse effect rates between people receiving corticosteroids and people receiving placebo (RR 1.04, 95% CI 0.71 to 1.51, n = 715). Authors' conclusions The available moderate-to high-quality evidence from randomised controlled trials showed significant benefit from treating Bell's palsy with corticosteroids."],["dc.identifier.doi","10.1002/14651858.CD001942.pub5"],["dc.identifier.eissn","1465-1858"],["dc.identifier.isi","000391289400005"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69684"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1361-6137"],["dc.relation.issn","1469-493X"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.title","Corticosteroids for Bell's palsy (idiopathic facial paralysis)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","CD001869"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","The Cochrane Database of Systematic Reviews"],["dc.contributor.author","Gágyor, Ildikó"],["dc.contributor.author","Madhok, Vishnu B."],["dc.contributor.author","Daly, Fergus"],["dc.contributor.author","Somasundara, Dhruvashree"],["dc.contributor.author","Sullivan, Michael"],["dc.contributor.author","Gammie, Fiona"],["dc.contributor.author","Sullivan, Frank"],["dc.date.accessioned","2018-11-07T10:04:13Z"],["dc.date.available","2018-11-07T10:04:13Z"],["dc.date.issued","2015"],["dc.description.abstract","Background Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. Significant morbidity can be associated with severe cases of Bell's palsy. Objectives To assess the effects of antiviral treatments alone or in combination with any other therapy for Bell's palsy. Search methods On 7 October 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, DARE, NHS EED, and HTA. We also reviewed the bibliographies of the identified trials and contacted trial authors and known experts in the field and relevant drug companies to identify additional published or unpublished data. We searched clinical trials registries for ongoing studies. Selection criteria We considered randomised controlled trials or quasi-randomised controlled trials of antivirals with and without corticosteroids versus control therapies for the treatment of Bell's palsy. We excluded trials that had a high risk of bias in several domains. Data collection and analysis Pairs of authors independently assessed trials for relevance, eligibility, and risk of bias, using standard Cochrane procedures. Main results Eleven trials, including 2883 participants, met the inclusion criteria and are included in the final analysis. We added four studies to the previous review for this update. Some of the trials were small, and a number were at high or unclear risk of bias. Other trials did not meet current best standards in allocation concealment and blinding. Incomplete recovery We found no significant benefit from adding antivirals to corticosteroids in comparison with corticosteroids alone for people with Bell's palsy (risk ratio (RR) 0.69, 95% confidence interval (CI) 0.47 to 1.02, n = 1715). For people with severe Bell's palsy (House-Brackmann scores of 5 and 6 or the equivalent in other scales), we found a reduction in the rate of incomplete recovery at month six when antivirals plus corticosteroids were used (RR 0.64, 95% CI 0.41 to 0.99, n = 478). The outcome for the participants receiving corticosteroids alone was significantly better than for those receiving antivirals alone (RR 2.09, 95% CI 1.36 to 3.20, n = 1169). The treatment effect of placebo was significantly lower than that of antivirals plus corticosteroids (RR 0.56, 95% CI 0.41 to 0.76, n = 658). Antivirals alone had a non-significant detrimental effect on the outcome compared with placebo (RR 1.10, 95% CI 0.87 to 1.40, n = 658). Motor synkinesis or crocodile tears In three trials comparing antivirals and corticosteroids with corticosteroids and placebo that assessed this outcome, we found a significant difference in long-term sequelae in favour of antivirals plus corticosteroids (RR 0.73, 95% CI 0.54 to 0.99, n = 869). Three trials comparing antivirals alone with corticosteroids alone investigating this outcome showed fewer sequelae with corticosteroids (RR 1.44, 95% CI 1.11 to 1.85, n = 873). We found no data on long-term sequelae for other comparisons. Adverse events Adverse event data were available in three studies giving comparison data on 1528 participants. None of the four comparisons (antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment; antivirals versus corticosteroids; antivirals plus corticosteroids versus placebo; antivirals versus placebo) showed significant differences in adverse events between treatment and control arms. We could find no correlation with specific treatment within these results. Authors' conclusions Moderate-quality evidence from randomised controlled trials showed no additional benefit from the combination of antivirals with corticosteroids compared to corticosteroids alone for the treatment of Bell's palsy of various degrees of severity. Moderate-quality evidence showed a small but just significant benefit of combination therapy compared with corticosteroids alone in severe Bell's palsy. Corticosteroids alone were more effective than antivirals alone and antivirals plus corticosteroids were more effective than placebo or no treatment. There was no benefit from antivirals alone over placebo. Moderate-quality evidence indicated that the combination of antivirals and corticosteroids reduced sequelae of Bell's palsy compared with corticosteroids alone. We found no significant increase in adverse events from the use of antivirals compared with either placebo or corticosteroids, based on moderate-quality evidence."],["dc.description.sponsorship","University of Dundee, UK"],["dc.identifier.doi","10.1002/14651858.CD001869.pub6"],["dc.identifier.isi","000209933300004"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38650"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1361-6137"],["dc.relation.issn","1469-493X"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","CC BY 4.0"],["dc.title","Antiviral treatment for Bell's palsy (idiopathic facial paralysis)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","600"],["dc.bibliographiccitation.lastpage","605"],["dc.contributor.author","Gágyor, Ildikó"],["dc.contributor.author","Abholz, Heinz-Harald"],["dc.contributor.editor","Kochen, Michael M."],["dc.date.accessioned","2021-09-10T10:15:00Z"],["dc.date.available","2021-09-10T10:15:00Z"],["dc.date.issued","2012"],["dc.description.edition","4"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/89324"],["dc.publisher","Thieme"],["dc.publisher.place","Stuttgart"],["dc.relation.isbn","978-3-13-141384-0"],["dc.relation.ispartof","Allgemeinmedizin und Familienmedizin"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.title","Ethische Fragen und Konflikte in der Allgemeinmedizin"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","9"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","European Journal of General Practice"],["dc.bibliographiccitation.lastpage","15"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Gagyor, Ildiko"],["dc.contributor.author","Himmel, Wolfgang"],["dc.contributor.author","Pierau, Andrea"],["dc.contributor.author","Chenot, Jean-Francois"],["dc.date.accessioned","2018-11-07T10:19:32Z"],["dc.date.available","2018-11-07T10:19:32Z"],["dc.date.issued","2016"],["dc.description.abstract","Background Although determinants of place of death have been investigated in several studies, there is a lack of knowledge on factors associated with dying at home from the general practice perspective. Objectives To identify factors associated with dying at home for patients in German general practice. Methods In a retrospective study, general practitioners of 30 general practices were asked to provide data for all patients aged 18 years or older who died within the last 12 months, using a self-developed questionnaire. 'Dying in hospital' was defined as dying in hospital or hospice and 'dying at home' as dying at one's usual residence including the nursing home. Multiple logistic regression analyses were used to determine factors associated with 'dying at home'; odds ratios (ORs) and their 95% confidence intervals (CI) were calculated as measures of effect size. Results Of 439 deceased patients, 52.2% died at home, and 47.8% died in hospital or hospice. Determinants for dying at home were patients' care in the last 48 hours of life by family members (OR: 7.8, 95% CI: 3.4-18.0), by general practitioners (GPs) (OR: 7.3, 4.2-12.9) and living in a nursing home (OR: 3.8, 1.7-8.3). In the adjusted model, low comorbidity was positively associated (OR: 3.2, 1.4-7.0), and low functional health status (Karnofsky performance status) was negatively associated with dying at home (OR: 0.3, 0.1-0.7). Conclusion Apart from patient-related factors such as comorbidity and health status, care by family members and GPs respectively, were determinants of dying at home."],["dc.description.sponsorship","Robert Bosch Foundation [12.5.1364.0028.0]"],["dc.identifier.doi","10.3109/13814788.2015.1117604"],["dc.identifier.isi","000372190400003"],["dc.identifier.pmid","26799953"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41678"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1751-1402"],["dc.relation.issn","1381-4788"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.title","Dying at home or in the hospital? An observational study in German general practice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","CD001869"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","The Cochrane Database of Systematic Reviews"],["dc.contributor.author","Gágyor, Ildikó"],["dc.contributor.author","Madhok, Vishnu B."],["dc.contributor.author","Daly, Fergus"],["dc.contributor.author","Somasundara, Dhruvashree"],["dc.contributor.author","Sullivan, Michael"],["dc.contributor.author","Gammie, Fiona"],["dc.contributor.author","Sullivan, Frank"],["dc.date.accessioned","2018-11-07T10:04:14Z"],["dc.date.available","2018-11-07T10:04:14Z"],["dc.date.issued","2015"],["dc.description.sponsorship","University of Dundee, UK"],["dc.identifier.doi","10.1002/14651858.CD001869.pub7"],["dc.identifier.isi","000209933500005"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38653"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1361-6137"],["dc.relation.issn","1469-493X"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.rights","CC BY 4.0"],["dc.title","Antiviral treatment for Bell's palsy (idiopathic facial paralysis) (Withdrawn Paper. 2015, art. no. CD001869)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","113"],["dc.bibliographiccitation.journal","Journal of Clinical Epidemiology"],["dc.bibliographiccitation.lastpage","121"],["dc.bibliographiccitation.volume","88"],["dc.contributor.author","Loudon, Kirsty"],["dc.contributor.author","Zwarenstein, Merrick"],["dc.contributor.author","Sullivan, Frank M."],["dc.contributor.author","Donnan, Peter T."],["dc.contributor.author","Gágyor, Ildikó"],["dc.contributor.author","Hobbelen, Hans J.S.M."],["dc.contributor.author","Althabe, Fernando"],["dc.contributor.author","Krishnan, Jerry A."],["dc.contributor.author","Treweek, Shaun"],["dc.date.accessioned","2020-12-10T14:25:00Z"],["dc.date.available","2020-12-10T14:25:00Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1016/j.jclinepi.2017.06.001"],["dc.identifier.issn","0895-4356"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72405"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.title","The PRECIS-2 tool has good interrater reliability and modest discriminant validity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","i415"],["dc.bibliographiccitation.journal","BMJ"],["dc.bibliographiccitation.volume","352"],["dc.contributor.author","Schmiemann, Guido"],["dc.contributor.author","Gagyor, Ildiko"],["dc.date.accessioned","2018-11-07T10:19:08Z"],["dc.date.available","2018-11-07T10:19:08Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1136/bmj.i415"],["dc.identifier.isi","000369313700009"],["dc.identifier.pmid","26823520"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41603"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bmj Publishing Group"],["dc.relation.issn","1756-1833"],["dc.title","IBUPROFEN V FOSFOMYCIN FOR UNCOMPLICATED URINARY TRACT INFECTION Authors' reply to Al-Wali and Hughes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","236"],["dc.bibliographiccitation.journal","Zeitschrift für Allgemeinmedizin"],["dc.bibliographiccitation.lastpage","238"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","Simmenroth-Nayda, Anne"],["dc.contributor.author","Gágyor, Ildikó"],["dc.date.accessioned","2021-09-14T13:29:11Z"],["dc.date.available","2021-09-14T13:29:11Z"],["dc.date.issued","2008"],["dc.identifier.doi","10.1055/s-2008-1080901"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/89396"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.title","Wem gehört die ambulante Palliativmedizin?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","E531"],["dc.bibliographiccitation.issue","17-18"],["dc.bibliographiccitation.journal","Canadian Medical Association Journal"],["dc.bibliographiccitation.lastpage","E532"],["dc.bibliographiccitation.volume","188"],["dc.contributor.author","Gagyor, Ildiko"],["dc.contributor.author","Madhok, Vishnu B."],["dc.contributor.author","Sullivan, Frank"],["dc.date.accessioned","2018-11-07T10:04:36Z"],["dc.date.available","2018-11-07T10:04:36Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1503/cmaj.160108"],["dc.identifier.isi","000390417900029"],["dc.identifier.pmid","27620636"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38733"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1488-2329"],["dc.relation.issn","0820-3946"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.title","A young woman with acute one-sided facial paralysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","241"],["dc.bibliographiccitation.lastpage","256"],["dc.contributor.author","Simmenroth-Nayda, Anne"],["dc.contributor.author","Gágyor, Ildikó"],["dc.contributor.author","Schindler, Thomas"],["dc.contributor.author","Engeser, Peter"],["dc.contributor.editor","Kochen, Michael M."],["dc.date.accessioned","2021-09-10T10:30:34Z"],["dc.date.available","2021-09-10T10:30:34Z"],["dc.date.issued","2012"],["dc.description.edition","4"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/89331"],["dc.publisher","Thieme"],["dc.publisher.place","Stuttgart"],["dc.relation.isbn","978-3-13-141384-0"],["dc.relation.ispartof","Allgemeinmedizin und Familienmedizin"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.title","Umgang mit Sterbenden und Hospizarbeit"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]